Halozyme Therapeutics Confirms It Anticipates $0 To Minimal Royalty Revenue Impact Based On Nov. 5 U.S. Centers For Medicare & Medicaid Services's Final Rule For Medicare Drug Price Negotiation Program
Benzinga Newsdesk 10 hours ago
News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026.